GRAL
Quality Rating
GRAL, a biotechnology company specializing in cancer detection diagnostics, exhibits a mixed Shariah compliance profile. The core business is permissible under Islamic principles, promoting health and welfare. However, financial ratios reveal challenges, including high liquidity (40.04%) and interest income (18.79%), leading to non-compliance in major standards. Excluded from all Shariah indices, the stock is classified as NON_COMPLIANT overall, with a B quality rating. Purification of 18.79% is required for any permissible income.
Purification Required
Significant purification required - exercise caution
Index Inclusion
Excluded from S&P Dow Jones Shariah Indices, MSCI Islamic Indices, FTSE Shariah Indices, and Dow Jones Islamic Market (DJIM)
Key Compliance Considerations
- High liquidity ratio of 40.04% exceeds thresholds across AAOIFI (30%), MSCI (33.33%), and S&P (33%)
- Interest income ratio of 18.79% surpasses the 5% impure income limit for all standards
Debt Ratio
3.8%
Liquidity Ratio
40.0%
Interest Income Ratio
18.8%
Purification
18.79%